|
1
|
Pellegriti G, Frasca F, Regalbuto C,
Squatrito S and Vigneri R: Worldwide increasing incidence of
thyroid cancer: Update on epidemiology and risk factors. J Cancer
Epidemiol. 2013:9652122013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Patil VS, Vijayakumar A and Natikar N:
Unusual presentation of cystic papillary thyroid carcinoma. Case
Rep Endocrinol. 2012:7327152012.PubMed/NCBI
|
|
3
|
Anil S, Radu B and Ricardo L: Metastatic
papillary thyroid carcinoma with absence of tumor focus in thyroid
gland. Am J Case Rep. 14:73–75. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Haugen BR, Alexander EK, Bible KC, Doherty
GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM,
Schlumberger M, et al: 2015 American thyroid association management
guidelines for adult patients with thyroid nodules and
differentiated thyroid cancer: The American thyroid association
guidelines task force on thyroid nodules and differentiated thyroid
cancer. Thyroid. 26:1–133. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Leboulleux S, Rubino C, Baudin E, Caillou
B, Hartl DM, Bidart JM, Travagli JP and Schlumberger M: Prognostic
factors for persistent or recurrent disease of papillary thyroid
carcinoma with neck lymph node metastases and/or tumor extension
beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol
Metab. 90:5723–5729. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Valinezhad Orang A, Safaralizadeh R and
Kazemzadeh-Bavili M: Mechanisms of miRNA-mediated gene regulation
from common downregulation to mRNA-specific upregulation. Int J
Genomics. 2014:9706072014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu S, Liu Y, Wang J, Guo Z, Zhang Q, Yu F,
Zhang Y, Huang K, Li Y, Song E, et al: Circulating microRNA
profiles as potential biomarkers for diagnosis of papillary thyroid
carcinoma. J Clin Endocrinol Metab. 97:2084–2092. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Swierniak M, Wojcicka A, Czetwertynska M,
Stachlewska E, Maciag M, Wiechno W, Gornicka B, Bogdanska M,
Koperski L, de la Chapelle A and Jazdzewski K: In-depth
characterization of the microRNA transcriptome in normal thyroid
and papillary thyroid carcinoma. J Clin Endocrinol Metab.
98:E1401–E1409. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takano Y, Masuda T, Iinuma H, Yamaguchi R,
Sato K, Tobo T, Hirata H, Kuroda Y, Nambara S, Hayashi N, et al:
Circulating exosomal microRNA-203 is associated with metastasis
possibly via inducing tumor-associated macrophages in colorectal
cancer. Oncotarget. 8:78598–78613. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hu Y, Wang L, Gu J, Qu K and Wang Y:
Identification of microRNA differentially expressed in three
subtypes of non-small cell lung cancer and in silico functional
analysis. Oncotarget. 8:74554–74566. 2017.PubMed/NCBI
|
|
11
|
Lohcharoenkal W, Mahapatra Das Mahapatra
K, Pasquali L, Crudden C, Kular L, Akkaya Ulum YZ, Zhang L, Xu
Landén N, Girnita L, Jagodic M, et al: Genome-wide screen for
MicroRNAs reveals a role for miR-203 in melanoma metastasis. J
Invest Dermatol. 138:882–892. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dusílková N, Bašová P, Polívka J, Kodet O,
Kulvait V, Pešta M, Trněný M and Stopka T: Plasma miR-155, miR-203,
and miR-205 are biomarkers for monitoring of primary cutaneous
T-cell lymphomas. Int J Mol Sci. 18(pii): E21362017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Benati M, Montagnana M, Danese E, Paviati
E, Giudici S, Franchi M and Lippi G: Evaluation of mir-203
expression levels and DNA promoter methylation status in serum of
patients with endometrial cancer. Clin Lab. 63:1675–1681. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zheng Y, Liu W, Guo L and Yang X: The
expression level of miR-203 in patients with gastric cancer and its
clinical significance. Pathol Res Pract. 213:1515–1518. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li E: Chromatin modification and
epigenetic reprogramming in mammalian development. Nat Rev Genet.
3:662–673. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou VW, Goren A and Bernstein BE:
Charting histone modifications and the functional organization of
mammalian genomes. Nat Rev Genet. 12:7–18. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bianco-Miotto T, Chiam K, Buchanan G,
Jindal S, Day TK, Thomas M, Pickering MA, O'Loughlin MA, Ryan NK,
Raymond WA, et al: Global levels of specific histone modifications
and an epigenetic gene signature predict prostate cancer
progression and development. Cancer Epidemiol Biomarkers Prev.
19:2611–2622. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Seligson DB, Horvath S, Shi T, Yu H, Tze
S, Grunstein M and Kurdistani SK: Global histone modification
patterns predict risk of prostate cancer recurrence. Nature.
435:1262–1266. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang Y, Xue K, Li Z, Zheng W, Dong W, Song
J, Sun S, Ma T and Li W: c-Myc regulates the CDK1/cyclin B1
dependent-G2/M cell cycle progression by histone H4 acetylation in
Raji cells. Int J Mol Med. 41:3366–3378. 2018.PubMed/NCBI
|
|
20
|
Chaturvedi P, Kalani A, Givvimani S, Kamat
PK, Familtseva A and Tyagi SC: Differential regulation of DNA
methylation versus histone acetylation in cardiomyocytes during
HHcy in vitro and in vivo: An epigenetic mechanism. Physiol
Genomics. 46:245–255. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bian X, Liang Z, Feng A, Salgado E and
Shim H: HDAC inhibitor suppresses proliferation and invasion of
breast cancer cells through regulation of miR-200c targeting CRKL.
Biochem Pharmacol. 147:30–37. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Swierczynski S, Klieser E, LLLig R,
Alinger-Scharinger B, Kiesslich T and Neureiter D: Histone
deacetylation meets miRNA: Epigenetics and post-transcriptional
regulation in cancer and chronic diseases. Expert Opin Biol Ther.
15:651–664. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu L, Jia Y, Yang XH, Han F, Zheng Y, Ni
Y, Chen X, Hong J, Liu JQ, Li Q, et al: MicroRNA-130b
transcriptionally regulated by histone H3 deacetylation renders Akt
ubiquitination and apoptosis resistance to 6-OHDA. Biochim Biophys
Acta Mol Basis Dis. 1863:1678–1689. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liebner DA and Shah MH: Thyroid cancer:
Pathogenesis and targeted therapy. Ther Adv Endocrinol Metab.
2:173–195. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Baldane S, Ipekci SH, Sozen M and
Kebapcilar L: Mean platelet volume could be a possible biomarker
for papillary thyroid carcinomas. Asian Pac J Cancer Prev.
16:2671–2674. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Aragon Han P, Weng CH, Khawaja HT,
Nagarajan N, Schneider EB, Umbricht CB, Witwer KW and Zeiger MA:
MicroRNA expression and association with clinicopathologic features
in papillary thyroid cancer: A systematic review. Thyroid.
25:1322–1329. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
de la Chapelle A and Jazdzewski K:
MicroRNAs in thyroid cancer. J Clin Endocrinol Metab. 96:3326–3336.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chou CK, Yang KD, Chou FF, Huang CC, Lan
YW, Lee YF, Kang HY and Liu RT: Prognostic implications of miR-146b
expression and its functional role in papillary thyroid carcinoma.
J Clin Endocrinol Metab. 98:E196–E205. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Visone R, Russo L, Pallante P, De Martino
I, Ferraro A, Leone V, Borbone E, Petrocca F, Alder H, Croce CM and
Fusco A: MicroRNAs (miR)-221 and miR-222, both overexpressed in
human thyroid papillary carcinomas, regulate p27Kip1 protein levels
and cell cycle. Endocr Relat Cancer. 14:791–798. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hong S, Yu S, Li J, Yin Y, Liu Y, Zhang Q,
Guan H, Li Y and Xiao H: MiR-20b displays tumor-suppressor
functions in papillary thyroid carcinoma by regulating the MAPK/ERK
signaling pathway. Thyroid. 26:1733–1743. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chi Y, Jin Q, Liu X, Xu L, He X, Shen Y,
Zhou Q, Zhang J and Jin M: miR-203 inhibits cell proliferation,
invasion, and migration of non-small-cell lung cancer by
downregulating RGS17. Cancer Sci. 108:2366–2372. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Selemetjev S, Savin S, Paunovic I, Tatic S
and Cvejic D: Concomitant high expression of survivin and vascular
endothelial growth factor-C is strongly associated with metastatic
status of lymph nodes in papillary thyroid carcinoma. J Cancer Res
Ther. 14 (Suppl):S114–S119. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu J, Sun W, Dong W, Wang Z, Qin Y, Zhang
T and Zhang H: HSP90 inhibitor NVP-AUY922 induces cell apoptosis by
disruption of the survivin in papillary thyroid carcinoma cells.
Biochem Biophys Res Commun. 487:313–319. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yan Y, Hu F, Wu W, Ma R and Huang H:
Expression characteristics of proteins of IGF-1R, p-Akt, and
survivin in papillary thyroid carcinoma patients with type 2
diabetes mellitus. Medicine (Baltimore). 96:e63932017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang YX, Li ML, Yu SG, Liu CM, Han Y and
Wang XY: The association between the Survivin A9194G exon
polymorphisms and papillary thyroid carcinoma risk in the Han
Chinese population. Pathol Res Pract. 209:151–154. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li H, Li X, Bai M, Suo Y, Zhang G and Cao
X: Matrine inhibited proliferation and increased apoptosis in human
breast cancer MCF-7 cells via upregulation of Bax and
downregulation of Bcl-2. Int J Clin Exp Pathol. 8:14793–14799.
2015.PubMed/NCBI
|
|
39
|
Ding JH, Yuan LY, Huang RB and Chen GA:
Aspirin inhibits proliferation and induces apoptosis of multiple
myeloma cells through regulation of Bcl-2 and Bax and suppression
of VEGF. Eur J Haematol. 93:329–339. 2014. View Article : Google Scholar : PubMed/NCBI
|
